Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories; Warner Chilcott
• Treatments: Azimilide

Criteria

Inclusion Criteria:

• patients who completed at least 12 months on study 2000098 before inclusion in this study

Exclusion Criteria:

• breast feeding or plan to become pregnant

• used ticlopidine

• were taking Class I or other Class III drugs